首页> 外文OA文献 >LivRelief varicose veins cream in the treatment of chronic venous insufficiency of the lower limbs: A 6-week single arm pilot study
【2h】

LivRelief varicose veins cream in the treatment of chronic venous insufficiency of the lower limbs: A 6-week single arm pilot study

机译:Livrefief varicose veins霜在治疗下肢慢性静脉功能不全:6周的单臂试验研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundChronic Venous Disease is characterized by morphological abnormalities of the venous system. Affected limbs are classified in increasing clinical severity with the Clinical Etiological Anatomical and Pathological system from C0 to C6. Limbs assessed at C3 through C6 meet the criteria of Chronic Venous Insufficiency. Chronic Venous Insufficiency of the Lower Limbs is a very common pathology affecting approximately ~40% of the world's population. This study observes the use of the LivRelief Varicose Vein Cream, a Natural Health Product that is licensed for sale by Health Canada, for use in the treatment of varicose veins.MethodsAn open label, single arm interventional, pilot study was conducted to determine the feasibility of recruitment and data collection in this population. To accomplish this, the cream was provided to all enrolled subjects. Subsequently, objective and subjective measures were performed at baseline and after 6 weeks of at-home use. Recruitment and data collection targets of at least 70% were established and the data collected at both timepoints were compared and analyzed using a paired t-test. Results were also reported as proportions where appropriate.ResultsA total of 32 subjects were enrolled. The pre-defined feasibility objectives for recruitment and data collection were met with the enrolment of 97% of all screened patients and the collection of 94% of all scheduled data. The most significant therapeutic improvement was seen in the results of the Venous Clinical Severity Score where 66% of the treated legs experienced a decrease in severity after 6 weeks of treatment. P values were <0.0001 and 0.0003 for the left and right leg, respectively.ConclusionIt is feasible to recruit and collect data with the chosen outcome assessments within this population. Preliminary results suggest that the product could improve some of the clinical symptoms associated with the presence varicose veins. These results warrant further exploration in a longer, randomized and placebo-controlled study.Trial registrationClinicaltrial.gov: NCT03653793.
机译:背景系静脉疾病的特征在于静脉系统的形态异常。受影响的肢体分为从C0至C6的临床病因解剖学和病理系统增加临床严重程度。在C3至C6评估的肢体符合慢性静脉功能不全的标准。下肢的慢性静脉功能不足是一个非常常见的病理,影响了世界上大约〜40%的人口。本研究观察了使用Livelief变化静脉霜,由卫生加拿大销售许可的天然健康产品,用于治疗静脉曲张静脉,单手臂介入,单手臂介入,进行试验研究以确定可行性本人招聘和数据收集。为此,将奶油提供给所有注册的受试者。随后,客观和主观措施在基线和家庭使用6周后进行。建立了至少70%的招聘和数据收集目标,并使用配对T检验进行比较和分析在两个时间点上收集的数据。结果也被报告为适当的比例。注册了32个科目的总共32个受试者。招聘和数据收集的预定可行性目标符合所有筛选患者的97%,并收集所有预定数据的94%。在静脉临床严重程度的结果中可以看到最显着的治疗改善,其中66%的治疗腿在治疗6周后严重程度经历了严重程度。左腿和右腿分别为<0.0001和0.0003 .Conclusionit是招募和收集数据在该人群中的所选结果评估的数据。初步结果表明该产品可以改善与存在静脉曲张相关的一些临床症状。这些结果在更长,随机和安慰剂控制的研究中提供进一步的探索.Tirial ringialClinicalTrial.gov:NCT03653793。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号